Skip to main content

Table 2 Estimated IC50 of NSC 617145 in HTLV-1-transformed and patient-derived cells

From: WRN-targeted therapy using inhibitors NSC 19630 and NSC 617145 induce apoptosis in HTLV-1-transformed adult T-cell leukemia cells

HTLV-1-transformed cell lines IC50 (μM)
MT-4 0.19 ± 0.042
C8166 0.22 ± 0.023
C91PL 0.21 ± 0.0091
1186.94 0.22 ± 0.063
ATL-derived cell lines IC50 (μM)
ED 0.15 ± 0.033
TL 0.17 ± 0.039
ATL-25 0.16 ± 0.007
ATL-43T 0.099 ± 0.013
ATL-55T 0.22 ± 0.0012
LMY-1 0.29 ± 0.0087
KK1 0.28 ± 0.032
SO4 0.14 ± 0.061
KOB 0.17 ± 0.031
  1. We tested the HTLV-1-transformed, ATL-derived cell lines (MT-4, C8166, C91PL, 1186.94, ED, TL, ATL-25, ATL-43T, ATL-55T, LMY1, KK1, SO4, KOB) with increasing doses of NSC 617145 (0.02, 0.2, and 2 μM), and cell count was used to measure the inhibition of cellular growth. We calculated the IC50 for every cell line by using logarithmic transformation and the values are reported in the table. Our analysis clearly shows that NSC 617145 is more potent in inhibiting cellular proliferation compared to NSC 19630